Arnicolide D: a multi-targeted anticancer sesquiterpene lactone—preclinical efficacy and mechanistic insights

• Published in: Naunyn-Schmiedeberg's archives of pharmacology Vol. 397; no. 9; pp. 6317 - 6336
• Main Authors: Mangalpady, Shivaprasad Shetty, Peña-Corona, Sheila I., Borbolla-Jiménez, Fabiola, Kaverikana, Rajesh, Shetty, Shobhitha, Shet, Vinayaka Babu, Almarhoon, Zainab M., Calina, Daniela, Leyva-Gómez, Gerardo, Sharifi-Rad, Javad
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2024; Springer Nature B.V
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Animals; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antineoplastic Agents, Phytogenic - pharmacokinetics; Antineoplastic Agents, Phytogenic - pharmacology; Antineoplastic Agents, Phytogenic - therapeutic use; Apoptosis; Apoptosis - drug effects; Archives & records; Asthma; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast carcinoma; Cancer therapies; Cell culture; Cell cycle; Cell growth; Cell Line, Tumor; Cell proliferation; Cell Proliferation - drug effects; Chemistry; Clinical trials; Colon; Colon cancer; Colorectal cancer; Cytotoxicity; Dosage; Herbal medicine; Humans; Infections; Keywords; Lactones - pharmacology; Lactones - therapeutic use; Medical Subject Headings-MeSH; Metastases; Metastasis; Molecular modelling; Nasopharyngeal carcinoma; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Neurosciences; Pharmacokinetics; Pharmacology; Pharmacology/Toxicology; Pharmacy; Prostate cancer; Review; Sesquiterpenes - pharmacokinetics; Sesquiterpenes - pharmacology; Sesquiterpenes - therapeutic use; Signal Transduction - drug effects; Stat3 protein; Throat cancer; TOR protein; Toxicity testing; Tumor cell lines; Anti-cancer mechanisms; Sesquiterpene lactone, Src degradation; PI3K/AKT/mTOR pathway; Arnicolide D; Apoptosis; Centipeda minima
• ISSN: 0028-1298; 1432-1912; 1432-1912
• DOI: 10.1007/s00210-024-03095-7

Arnicolide D, a potent sesquiterpene lactone from Centipeda minima , has emerged as a promising anticancer candidate, demonstrating significant efficacy in inhibiting cancer cell proliferation, inducing apoptosis, and suppressing metastasis across various cancer models. This comprehensive study delves into the molecular underpinnings of Arnicolide D’s anticancer actions, emphasizing its impact on key signaling pathways such as PI3K/AKT/mTOR and STAT3, and its role in modulating cell cycle and survival mechanisms. Quantitative data from preclinical studies reveal Arnicolide D’s dose-dependent cytotoxicity against cancer cell lines, including nasopharyngeal carcinoma, triple-negative breast cancer, and human colon carcinoma, showcasing its broad-spectrum anticancer potential. Given its multifaceted mechanisms and preclinical efficacy, Arnicolide D warrants further investigation in clinical settings to validate its therapeutic utility against cancer. The evidence presented underscores the need for rigorous pharmacokinetic and toxicological studies to establish safe dosing parameters for future clinical trials.